BACKGROUND: Donor-specific transfusion (DST) and a brief course of anti-CD154 monoclonal antibody (mAb) induces permanent islet and prolonged skin allograft survival in mice. Induction of skin allograft survival requires the presence of CD4 cells and deletion of alloreactive CD8 cells. The specific roles of CD4 and CD4CD25 cells and the mechanism(s) by which they act are not fully understood. METHODS: We used skin and islet allografts, a CD8 T cell receptor (TCR) transgenic model system, and in vivo depleting antibodies to analyze the role of CD4 cell subsets in regulating allograft survival in mice treated with DST and anti-CD154 mAb. RESULTS: Deletion of CD4 or CD25 cells during costimulation blockade induced rapid rejection of...
BACKGROUND: Treatment with a single donor-specific transfusion (DST) plus a brief course of anti-CD1...
BACKGROUND: Treatment with anti-CD154 monoclonal antibody (mAb) plus a donor-specific transfusion (D...
<p>B6 mice were treated with MHC I + IL-2/anti-IL-2 and subsequent MHC II + IL-2 prior to transplant...
Treatment of mice with a single donor-specific transfusion (DST) plus a brief course of anti-CD154 m...
A two-element protocol consisting of one donor-specific transfusion (DST) plus a brief course of ant...
BACKGROUND: Treatment with a donor-specific transfusion (DST) and a brief course of anti-mouse CD154...
Treatment of C57BL/6 mice with one transfusion of BALB/c spleen cells and anti-CD154 (anti–CD40-liga...
Treatment of C57BL/6 mice with one transfusion of BALB/c spleen cells and anti-CD154 (anti-CD40-liga...
Treatment of C57BL/6 mice with one transfusion of BALB/c spleen cells and a brief course of anti-CD1...
Treatment of mice with a single donor-specific transfusion plus a brief course of anti-CD154 mAb uni...
BACKGROUND: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve s...
Anti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet trans...
Clinical islet transplantation is a successful procedure that can improve the quality of life in rec...
Background. Islet allograft rejection in sensitized recipients is difficult to control by costimulat...
BACKGROUND: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve s...
BACKGROUND: Treatment with a single donor-specific transfusion (DST) plus a brief course of anti-CD1...
BACKGROUND: Treatment with anti-CD154 monoclonal antibody (mAb) plus a donor-specific transfusion (D...
<p>B6 mice were treated with MHC I + IL-2/anti-IL-2 and subsequent MHC II + IL-2 prior to transplant...
Treatment of mice with a single donor-specific transfusion (DST) plus a brief course of anti-CD154 m...
A two-element protocol consisting of one donor-specific transfusion (DST) plus a brief course of ant...
BACKGROUND: Treatment with a donor-specific transfusion (DST) and a brief course of anti-mouse CD154...
Treatment of C57BL/6 mice with one transfusion of BALB/c spleen cells and anti-CD154 (anti–CD40-liga...
Treatment of C57BL/6 mice with one transfusion of BALB/c spleen cells and anti-CD154 (anti-CD40-liga...
Treatment of C57BL/6 mice with one transfusion of BALB/c spleen cells and a brief course of anti-CD1...
Treatment of mice with a single donor-specific transfusion plus a brief course of anti-CD154 mAb uni...
BACKGROUND: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve s...
Anti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet trans...
Clinical islet transplantation is a successful procedure that can improve the quality of life in rec...
Background. Islet allograft rejection in sensitized recipients is difficult to control by costimulat...
BACKGROUND: Anti-CD154 (MR1) monoclonal antibody (mAb) and rapamycin (RAPA) treatment both improve s...
BACKGROUND: Treatment with a single donor-specific transfusion (DST) plus a brief course of anti-CD1...
BACKGROUND: Treatment with anti-CD154 monoclonal antibody (mAb) plus a donor-specific transfusion (D...
<p>B6 mice were treated with MHC I + IL-2/anti-IL-2 and subsequent MHC II + IL-2 prior to transplant...